Enforma contests FTC allegations
This article was originally published in The Tan Sheet
Pointing to 19 studies as evidence of its Chitozyme weight-loss supplement's efficacy, company says FTC's recent contempt motion is "frivolous" and commission will be unable to provide clear and convincing evidence that Enforma lacks adequate substantiation for its ad claims. Enforma asserts FTC is using an undefined standard for "competent and reliable scientific evidence" and suggests commission should clarify this standard by telling Enforma what studies it considers vital to marketing Chitozyme. Firm says it has turned over to FTC studies on Carb Trapper Plus, and notes its products carry money-back guarantees, thereby refuting FTC's claim that consumers have suffered financial harm (1"The Tan Sheet" Aug. 5, 2002, p. 5). Enforma says it is considering suing FTC if company prevails in present action. Hearing on FTC's contempt motion, preliminary injunction request is scheduled for Sept. 30...
You may also be interested in...
Enforma Natural Products could be hit with civil contempt charges for the third time if FTC determines the firm is making unsubstantiated advertising and marketing claims for its Carb Trapper Plus weight-loss product
Using artificial intelligence and strict data collection protocol, ObvioHealth hopes to digitize clinical trials with the assistance of medical devices and consumer technology.
The developers of eleven new drugs could learn this week whether the European Medicines Agency will set them on course for pan-EU marketing approval.